Ethical Frontiers in Biotechnology
Exploring ethical issues in bioscience, engineering, health, and technology
Ethical Frontiers in Biotechnology is a monthly seminar series, hosted by Professor Insoo Hyun, PhD, explores issues at the intersection of ethics, technology, and bioscience with an eye toward practical approaches, policies and ethical responsibilities.
Invited experts will discuss the state of the science regarding chimeras, brain organoids, editing embryos, engineering living systems and other controversial frontiers of health-related knowledge and new applications. Interactive discussion will be part of each seminar.
Join the email list for upcoming event information and register below.
Thursday, February 13, 2020, 5 p.m. ET
Speaker: Jianping Fu, MS, PhD (University of Michigan)
Scientists are now able to explore important milestones in early human development which, until recently, have remained inaccessible to scientific exploration. Using extended culture systems of fertility clinic embryos alongside stem cell-based models of post-implantation human development (so-called "synthetic embryos"), researchers can now explore the "black box" of human development -- i.e., the developmental point just beyond implantation, when most women do not know they are pregnant and when many birth defects and miscarriages occur.
What can be learned by culturing natural embryos up to the 14 day regulatory limit? How can stem cell-based embryo models be used to advance human health? If embryo models are derived from patients' body cells, would this be tantamount to human cloning? What new ethical and policy questions do these advances raise? Do these new questions threaten the potential benefits of this research?
Interactive discussion will follow the presentation.
Embryo Editing for Reproduction and Research
Thursday, December 5, 2019, 5 p.m. ET
For individuals with a family history of a serious genetic disease, one perceived benefit of human germline modification would be to remove harmful genes, and consequently the threat of the disease for all their descendants. This allows carriers of genetic disease to avoid transmitting genetic harms to their offspring, while remaining genetically connected to their children.
Although society has pondered for decades the possibility of one day creating "designer babies," first to overcome genetic diseases, then later to include socially-desirable genetic traits, recent advances in genome-editing technologies have rapidly moved these discussions from the realm of science fiction toward science reality.
Drs. Insoo Hyun and Catherine Racowsky discussed the clinical and non-clinical (basic science) applications of human embryo editing research, how the technical challenges impact the ethics of attempting to use embryo editing in an assisted reproduction context, and the prospects of pursuing reproductive uses of embryo editing in the future.
The Plasticity of Human Cells: Synthetic human biology and beyond
Thursday, November 7, 2019, 5 p.m. ET
Induced pluripotency is a technology that can reprogram any cell in the human body into an embryonic stem cell-like state. From this reprogrammed state, skin or blood samples from patients, for example, can be easily transformed in the lab into neurons, liver cells, muscle, etc.
This amazing "plasticity" of human cells opens up exciting new possibilities for patient diagnosis and treatment, anti-aging research, organ generation, and more. These possibilities inspire hope for new cures in the future, but many may wonder whether there ought to be ethical limits to how we harness the power of human plasticity.
Thursday, October, 3, 2019, 5 p.m.
Over 22 million patients in the U.S. live with rare genetic diseases for which there are no FDA-approved treatments. Over 3.5 million of these patients are children who will die before the age of five. While genome sequencing can help diagnose these patients, it is far too long and costly to develop treatments for their orphan diseases through usual forms of scientific and pharmaceutical investment.
Using a case study from Boston Children's Hospital, Drs. Timothy Yu and Insoo Hyun discuss the scientific and ethical challenges facing single-patient (N=1) trials, as well as the opportunities presented by this entrée into what may be termed "hyper-personalized medicine."
Clinical Trials and Stem Cell Tourism
Thursday, September 5, 2019, 5 p.m.
Insoo Hyun and Harvard Medical School Dean George Q. Daley will discuss the scientific and ethical challenges surrounding stem cell-based clinical trials and attempts at medical innovation using patients' own stem cells.
How are the ethical and technical challenges facing the clinical translation of stem cell science exacerbated by the growing global phenomenon of "stem cell tourism"?
The Science and Ethics of Human/Animal Chimera Research
Thursday, May 16, 2019
Stem cell-based human/animal chimera research involves the transfer of human stem cells into animal hosts at various stages of development. The purpose of this research is to introduce localized human biological characteristics into laboratory animals to advance stem cell science, developmental biology, and many areas of biomedicine. Human/animal chimera research has existed without much controversy for decades outside of stem cell research, resulting in, for example, mouse models of human cancer and the human immune system. However, the possibility of acute levels of human/animal mixing in stem cell-based chimeras is of special concern to many.
Insoo Hyun and Willy Lensch, PhD guided attendees through the scientific and ethical issues raised by stem cell-based chimera research, drawing on years of Dr. Lensch’s chimera research experience and Dr. Hyun’s externally funded bioethics research and published work in this area.
This series is hosted and organized by the Center for Bioethics at Harvard Medical School and co-sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School with support from the Oswald DeN. Cammann Fund at Harvard University.